![IMCAS 2024 Galderma aesthetic portfolio](/sites/default/files/Website_CR_Release.png)
25 . 01 .2024
Press release
IMCAS 2024: Galderma to present latest updates from its unparalleled aesthetics portfolio reinforcing its leadership position
![Restylane® SHAYPE™](/sites/default/files/Website_News.png)
22 . 01 .2024
Press release
Galderma announces regulatory approval for Restylane® SHAYPE™, a new hyaluronic acid injectable designed for augmenting the chin region
![](/sites/default/files/Website_1.png)
17 . 01 .2024
Press release
TOXINS 2024: Galderma’s phase III RelabotulinumtoxinA results demonstrate positive efficacy and long duration of effect when treating frown lines and crow’s feet simultaneously
![Dr Shridharani News](/sites/default/files/Website_News_DrShridharani.png)
07 . 12 .2023
News story
Centering patient needs: Dr. Shridharani's shared values with Galderma
![QM1114](/sites/default/files/Thumbnail_Website.png)
30 . 11 .2023
Press release
Results from Galderma’s phase IIIb trials demonstrate rapid and long-lasting effect of RelabotulinumtoxinA on crow’s feet and frown lines
![Q3 2023 results](/sites/default/files/Q3Thumbnail.png)
21 . 11 .2023
Press release
Galderma reports record net sales of over 3 B USD for the first nine months of 2023 with strong growth momentum across all product categories